Details for Patent: 10,695,323
✉ Email this page to a colleague
Which drugs does patent 10,695,323 protect, and when does it expire?
Patent 10,695,323 protects JAYPIRCA and is included in one NDA.
This patent has eighty-three patent family members in forty countries.
Summary for Patent: 10,695,323
| Title: | Compounds useful as kinase inhibitors |
| Abstract: | This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases. |
| Inventor(s): | Nicolas Guisot |
| Assignee: | Loxo Oncology Inc |
| Application Number: | US16/063,542 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,695,323
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-001 | Jan 27, 2023 | RX | Yes | No | 10,695,323 | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR | ⤷ Start Trial | ||
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-001 | Jan 27, 2023 | RX | Yes | No | 10,695,323 | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR | ⤷ Start Trial | ||
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-002 | Jan 27, 2023 | RX | Yes | Yes | 10,695,323 | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR | ⤷ Start Trial | ||
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-002 | Jan 27, 2023 | RX | Yes | Yes | 10,695,323 | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,695,323
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3390395 | ⤷ Start Trial | CA 2024 00006 | Denmark | ⤷ Start Trial |
| European Patent Office | 3390395 | ⤷ Start Trial | 301262 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3390395 | ⤷ Start Trial | LUC00330 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 3390395 | ⤷ Start Trial | PA2024506 | Lithuania | ⤷ Start Trial |
| European Patent Office | 3390395 | ⤷ Start Trial | CR 2024 00006 | Denmark | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
